MA34742B1 - Proteines de liaison à l'antigène - Google Patents

Proteines de liaison à l'antigène

Info

Publication number
MA34742B1
MA34742B1 MA36018A MA36018A MA34742B1 MA 34742 B1 MA34742 B1 MA 34742B1 MA 36018 A MA36018 A MA 36018A MA 36018 A MA36018 A MA 36018A MA 34742 B1 MA34742 B1 MA 34742B1
Authority
MA
Morocco
Prior art keywords
binding proteins
antigen binding
osm
methods
relates
Prior art date
Application number
MA36018A
Other languages
English (en)
Inventor
Gary Peter Bembridge
Chun-Wa Chung
Maria Feeney
Susannah Karen Ford
Ian Kirby
Ruth Mcadam
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45001764&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34742(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA34742B1 publication Critical patent/MA34742B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Volume Flow (AREA)

Abstract

L'invention se réfère à des protéines de liaison à l'antigène et à des fragments de celles-ci qui se lient spécifiquement à l'oncostatine M (OSM), en particulier l'OSM humaine (hOSM), et qui inhibent la liaison de l'OSM au récepteur gp130 mais n'interagissent pas directement avec des résidus du site II. L'invention concerne aussi un procédé d'humanisation d'anticorps. Elle concerne en outre des compositions pharmaceutiques, des procédés de criblage et des méthodes de traitement médical.
MA36018A 2010-11-23 2013-06-19 Proteines de liaison à l'antigène MA34742B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41649510P 2010-11-23 2010-11-23
PCT/EP2011/070604 WO2012069433A2 (fr) 2010-11-23 2011-11-21 Protéines de liaison à l'antigène

Publications (1)

Publication Number Publication Date
MA34742B1 true MA34742B1 (fr) 2013-12-03

Family

ID=45001764

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36018A MA34742B1 (fr) 2010-11-23 2013-06-19 Proteines de liaison à l'antigène

Country Status (38)

Country Link
US (4) US8916695B2 (fr)
EP (3) EP2643352B1 (fr)
JP (2) JP6351973B2 (fr)
KR (2) KR20130119948A (fr)
CN (1) CN103328508B (fr)
AR (1) AR083937A1 (fr)
AU (1) AU2011333878B2 (fr)
BR (1) BR112013012627A2 (fr)
CA (1) CA2818534A1 (fr)
CL (1) CL2013001466A1 (fr)
CO (1) CO6801627A2 (fr)
CY (1) CY1120448T1 (fr)
DK (1) DK2643352T3 (fr)
DO (1) DOP2013000113A (fr)
EA (1) EA027256B1 (fr)
ES (1) ES2681949T3 (fr)
HR (1) HRP20181092T1 (fr)
HU (1) HUE039412T2 (fr)
IL (1) IL226157B (fr)
JO (1) JO3455B1 (fr)
LT (1) LT2643352T (fr)
MA (1) MA34742B1 (fr)
ME (1) ME03069B (fr)
MX (1) MX351887B (fr)
MY (1) MY170404A (fr)
NZ (1) NZ610464A (fr)
PE (1) PE20140519A1 (fr)
PL (1) PL2643352T3 (fr)
PT (1) PT2643352T (fr)
RS (1) RS57502B1 (fr)
SG (2) SG190232A1 (fr)
SI (1) SI2643352T1 (fr)
TR (1) TR201810773T4 (fr)
TW (1) TWI504609B (fr)
UA (1) UA111954C2 (fr)
UY (1) UY33743A (fr)
WO (1) WO2012069433A2 (fr)
ZA (1) ZA201303541B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2627356B1 (fr) 2010-10-13 2019-05-22 Janssen Biotech, Inc. Anticorps contre l'oncostatine m humaine et procédés d'utilisation
BR112013012627A2 (pt) 2010-11-23 2016-10-04 Glaxo Group Ltd proteína de ligação de antígeno, polinucleotídeo, composição farmacêutica, e uso da referida composição
US9550828B2 (en) 2013-09-05 2017-01-24 Boise State University Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders
EP3197480A1 (fr) 2014-09-24 2017-08-02 Universita' Degli Studi Di Padova Composition pour induire la mobilisation des cellules souches de la moelle osseuse
EP3250599B1 (fr) 2015-01-29 2021-04-14 Oxford University Innovation Limited Biomarqueur
GB201614627D0 (en) * 2016-08-30 2016-10-12 Glaxosmithkline Ip Dev Ltd Antigen binding proteins
FR3090637A1 (fr) * 2018-12-21 2020-06-26 Universite De Poitiers Protéine de liaison spécifique capable de se lier spécifiquement à l’oncostatine M humaine (hOSM) et ses utilisations.
US11633457B2 (en) 2019-04-11 2023-04-25 Boise State University Pharmaceutical compositions comprising oncostatin m (OSM) antagonist derivatives and methods of use

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4666884A (en) 1984-04-10 1987-05-19 New England Deaconess Hospital Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0307434B2 (fr) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Anticorps alteres
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
EP0521985B1 (fr) 1990-03-20 1997-09-24 The Trustees Of Columbia University In The City Of New York Anticorps chimeriques utilisant des ligands de liaison de recepteurs a la place de leur region constante
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5783672A (en) 1994-05-26 1998-07-21 Immunex Corporation Receptor for oncostatin M
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5747035A (en) 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
WO1997043316A1 (fr) 1996-05-10 1997-11-20 Beth Israel Deaconess Medical Center, Inc. Molecules physiologiquement actives a demi-vies prolongees et methode d'utilisation de ces dernieres
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US5958442A (en) * 1997-10-24 1999-09-28 Bristol-Myers Squibb Company Oncostatin M for treating inflammation
EP1060194A1 (fr) 1998-02-25 2000-12-20 Lexigen Pharmaceuticals Corp. Amelioration de la demi-vie circulante de proteines hybrides a base d'anticorps
GB9806530D0 (en) * 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
AU770555B2 (en) 1998-08-17 2004-02-26 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
KR100887482B1 (ko) 1999-01-15 2009-03-10 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
EP3031917A1 (fr) 1999-04-09 2016-06-15 Kyowa Hakko Kirin Co., Ltd. Procédé de contrôle de l'activité d'une molécule immunologiquement fonctionnelle
US7504256B1 (en) 1999-10-19 2009-03-17 Kyowa Hakko Kogyo Co., Ltd. Process for producing polypeptide
EP1148065B1 (fr) * 2000-04-21 2008-01-02 CONARIS research institute AG Protéines de fusion comprenant deux molécules gp130 solubles
AU2002218166A1 (en) 2000-09-08 2002-03-22 Universitat Zurich Collections of repeat proteins comprising repeat modules
US6374470B1 (en) 2000-10-06 2002-04-23 Milliken & Company Face plate for spun-like textured yarn
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
WO2002060919A2 (fr) 2000-12-12 2002-08-08 Medimmune, Inc. Molecules a demi-vies longues, compositions et utilisations de celles-ci
MXPA05000511A (es) * 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
NZ581474A (en) 2001-08-03 2011-04-29 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
JP5133494B2 (ja) 2001-08-10 2013-01-30 アバディーン ユニバーシティ 抗原結合ドメイン
EP1641818B1 (fr) 2003-07-04 2008-12-03 Affibody AB Polypeptides presentant une affinite de liaison pour le recepteur 2 du facteur de croissance epidermique humain (her2)
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
WO2005047324A2 (fr) * 2003-11-10 2005-05-26 Schering Corp Anticorps anti-interleukine-10
MXPA06006406A (es) 2003-12-05 2007-03-21 Adnexus Therapeutics Inc Inhibidores de receptores de factor de crecimiento endotelial vascular tipo 2.
GB0407197D0 (en) * 2004-03-30 2004-05-05 Glaxo Group Ltd Immunoglobulins
PE20060287A1 (es) * 2004-03-30 2006-05-16 Glaxo Group Ltd INMUNOGLOBULINAS DE UNION SELECTIVA A hOSM
AU2005269759A1 (en) 2004-07-21 2006-02-09 Glycofi, Inc. Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
JP4997108B2 (ja) 2005-07-22 2012-08-08 協和発酵キリン株式会社 遺伝子組換え抗体組成物
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
EP2027157B1 (fr) * 2006-05-25 2014-08-06 Glaxo Group Limited Anticorps anti-interleukine-18, modifies et humanises
EP1958957A1 (fr) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprenant un partie caractéristique des protéines appellées "Knottins"
WO2010056893A1 (fr) * 2008-11-13 2010-05-20 Imclone Llc Humanisation et optimisation d’affinité d’anticorps
EP2627356B1 (fr) * 2010-10-13 2019-05-22 Janssen Biotech, Inc. Anticorps contre l'oncostatine m humaine et procédés d'utilisation
BR112013012627A2 (pt) 2010-11-23 2016-10-04 Glaxo Group Ltd proteína de ligação de antígeno, polinucleotídeo, composição farmacêutica, e uso da referida composição

Also Published As

Publication number Publication date
RS57502B1 (sr) 2018-10-31
SG10201500388PA (en) 2015-03-30
CO6801627A2 (es) 2013-11-29
CY1120448T1 (el) 2019-07-10
US20210017270A1 (en) 2021-01-21
BR112013012627A2 (pt) 2016-10-04
CL2013001466A1 (es) 2014-06-27
NZ610464A (en) 2015-02-27
EP2643352B1 (fr) 2018-05-02
JP6351973B2 (ja) 2018-07-04
CN103328508A (zh) 2013-09-25
US20130251724A1 (en) 2013-09-26
SG190232A1 (en) 2013-06-28
MX2013005843A (es) 2013-07-05
IL226157B (en) 2020-10-29
US8916695B2 (en) 2014-12-23
CA2818534A1 (fr) 2012-05-31
EA201390537A1 (ru) 2014-01-30
CN103328508B (zh) 2015-12-16
WO2012069433A2 (fr) 2012-05-31
US20170152312A1 (en) 2017-06-01
EP3369744A1 (fr) 2018-09-05
DOP2013000113A (es) 2013-12-15
AU2011333878A1 (en) 2013-05-09
US10808029B2 (en) 2020-10-20
US9605063B2 (en) 2017-03-28
KR101947356B1 (ko) 2019-02-12
MY170404A (en) 2019-07-27
UA111954C2 (uk) 2016-07-11
MX351887B (es) 2017-11-01
UY33743A (es) 2012-06-29
JP2017078072A (ja) 2017-04-27
KR20180110199A (ko) 2018-10-08
TWI504609B (zh) 2015-10-21
US20150064201A1 (en) 2015-03-05
AR083937A1 (es) 2013-04-10
JO3455B1 (ar) 2020-07-05
PT2643352T (pt) 2018-08-01
KR20130119948A (ko) 2013-11-01
ES2681949T3 (es) 2018-09-17
TR201810773T4 (tr) 2018-08-27
ME03069B (fr) 2019-01-20
PL2643352T3 (pl) 2018-10-31
ZA201303541B (en) 2014-11-26
EP2643352A2 (fr) 2013-10-02
EA027256B1 (ru) 2017-07-31
JP2014507373A (ja) 2014-03-27
HUE039412T2 (hu) 2018-12-28
LT2643352T (lt) 2018-08-10
WO2012069433A3 (fr) 2012-08-09
AU2011333878B2 (en) 2016-01-14
SI2643352T1 (sl) 2018-12-31
IL226157A0 (en) 2013-06-27
HRP20181092T1 (hr) 2018-09-21
EP3211009A1 (fr) 2017-08-30
DK2643352T3 (en) 2018-07-30
TW201235358A (en) 2012-09-01
PE20140519A1 (es) 2014-04-30

Similar Documents

Publication Publication Date Title
MA34742B1 (fr) Proteines de liaison à l'antigène
MA35208B1 (fr) Protéines de liaison à bcma (cd269/tnfrsf17)
EA200970262A1 (ru) Композиции и способы, относящиеся к антителам к глюкагоновым рецепторам
MA33402B1 (fr) Compositions et procédés de ciblage de la proteine c3b de complément par des anticorps
EA200800355A1 (ru) Нейтрализующие антитела человека против b7rp1
SG151292A1 (en) Immunoglobulins
MA33387B1 (fr) Polypeptides et procede de traitement
UA109633C2 (uk) Антитіло людини проти тканинного фактора
WO2008105886A3 (fr) Anticorps spécifiques fcgriib humanisés, et leurs procédés d'utilisation
MA32725B1 (fr) Anticorps contre l'il 17 humaine et utilisations associees
PE20091196A1 (es) Anticuerpos contra el vegf completamente humano, composiciones y metodos
NO20054170L (no) Antistoff mot human IL-21 reseptor og anvendelser derav
MY159787A (en) High affinity antibodies to human il-6 receptor
WO2005110474A3 (fr) ANTICORPS SPÉCIFIQUES FcϜRIIB HUMANISÉS ET MÉTHODES D’UTILISATION
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
EA201190132A1 (ru) Гуманизированные антитела, связывающиеся с cd19, и их применение
MA38161A1 (fr) Anticorps anti-bmp-6
MA37761A1 (fr) Protéines de liaison à un antigène antagoniste d'un double récepteur et leurs utilisations
UA113623C2 (uk) Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi)
EA202091747A1 (ru) Составы антитела b7-h4
TH149802A (th) โปรตีนจับเกาะแอนติเจน
MY185086A (en) Human anti-b7rp1 neutralizing antibodies
MY152169A (en) Human anti-b7rp1 neutralizing antibodies
UA97645C2 (ru) АНТИТЕЛО, СПЕЦИФИЧЕСКИ СВЯЗЫВАЮЩЕЕ РЕЦЕПТОР ИНТЕРЛЕЙКИНА-6 ЧЕЛОВЕКА (hIL-6R)
UA108207C2 (xx) Високоафінне людське антитіло до людського ангіопоетину-2